MET
Other names: MET exon 14 skipping, MET amplification, MET exon 14
MET changes can be exon 14 skipping or amplification; the two are discussed differently in treatment planning.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Plain explanation
MET is a gene involved in cell growth signaling. Changes in this gene can make these signals uncontrollable. The type of change determines how the results are interpreted.
Clinical meaning
MET exon 14 skipping is generally discussed as a group that can be directed to MET inhibitors. MET amplification requires attention to the level of amplification and is often more complex, because it is also related to resistance.
Testing methods
- Next-generation sequencing (NGS)
A test that reads many genes from one tumour sample to find actionable changes.
- FISH (fluorescence in situ hybridisation)
A test that detects changes in the number or arrangement of genetic material in tumour cells.
- Liquid biopsy (ctDNA)
A blood test that looks for tumour genetic material to supplement or partly replace tissue testing.
A negative result does not always mean the marker is absent
Test sensitivity differs by sample type and method. Results need to be read together with the pathology report and clinical condition.
What needs verification
- Type of MET change and measurement value when there is amplification.
- Time of examination relative to previous therapy.
- Has the tumor been re-examined after progression?
- Availability of MET inhibitor drugs at destination facilities.
Related drugs
- Tepotinib
Selective MET inhibitor
- Capmatinib
Selective MET inhibitor
- Savolitinib
Selective MET inhibitor
- Crizotinib
ALK/ROS1/MET inhibitor
A link here means the marker is often part of considering a drug category, not a recommendation to use it.
Guides discussing this marker
Written to help prepare questions and documents, not to replace a doctor's assessment.
Clinical trials
Studies mentioning this marker
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT01639508Phase 2Combination regimen
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Lung Cancer | biomarker: ROS1, MET, RET, NTRK
United States7 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker ROS1.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT01639508Not verified
NCT04928846Phase 3Combination regimen
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer | biomarker: EGFR, MET | Chemotherapy
United States, Argentina, Australia +29317 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Chemotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04928846Not verified
NCT06106802Phase 2Targeted therapy
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Lung Cancer | biomarker: EGFR, MET | Targeted therapy
South Korea1 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06106802Not verified
Check options based on your result
Share the MET result you have so we can explain which categories to discuss with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Lung Cancer
Cancer type
Reason: Related through a biomarker
- Newly diagnosed lung cancer
Decision situation
Reason: Related through a biomarker
- Metastatic lung cancer
Decision situation
Reason: Related through a biomarker
- MET amplification
Molecular alteration
Reason: Related through a biomarker
- MET exon 14 skipping
Molecular alteration
Reason: Related through a biomarker
- Targeted therapy
Treatment category
Reason: Related through a biomarker
To check
- FISH (fluorescence in situ hybridisation)
Diagnostic test
Reason: Diperiksa melalui
- Liquid biopsy (ctDNA)
Diagnostic test
Reason: Diperiksa melalui
- Next-generation sequencing (NGS)
Diagnostic test
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.